Astex Pharmaceuticals to Present AT26893 at EASL
News Apr 16, 2012
Astex Pharmaceuticals, Inc. has announced that it will present data on AT26893, a novel, first-in-class, direct acting antiviral agent (DAA) against Hepatitis C Virus (HCV) at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL): The International Liver Congress™, April 18 to 22, 2012 in Barcelona, Spain.
The following presentations are scheduled for Friday, April 20th from 12:30 to 2:00 pm during the poster session: Viral Hepatitis C: Experimental (virology)
• Abstract No. 19057: Fragment based discovery and cellular validation of a novel allosteric binding site on the full length HCV NS3/4a enzyme.
• Abstract No. 19064: Pre-clinical characterization of a novel allosteric inhibitor of the HCV full length NS3/4a protein.
The NS3 protein is essential for viral replication and represents a validated HCV therapeutic target.
Astex has used its fragment-based drug discovery approach, Pyramid™, to discover and target a novel allosteric binding site on the full length HCV NS3 protease - helicase enzyme.
Compounds binding at this site have a novel mode of action and a different resistance profile compared to NS3 active-site protease inhibitors and these data will be presented at EASL.
Astex scientists will also present data on the characterization of AT26893 that has entered formal preclinical development in preparation for an IND filing.
This research program, which has been supported with £2 million of funding from the Wellcome Trust Seeding Drug Discovery initiative, is wholly owned by Astex Pharmaceuticals.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Simple Sugar Prevents Neurodegeneration in Lysosomal Storage DiseaseNews
New therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB)READ MORE